ArticleCancers2022

Biglycan Interacts with Type I Insulin-like Receptor (IGF-IR) Signaling Pathway to Regulate Osteosarcoma Cell Growth and Response to Chemotherapy.

Eirini-Maria Giatagana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.